新型B细胞淋巴瘤-2抑制剂——lisaftoclax  

A novel inhibitor of B-cell lymphoma-2:lisaftoclax

作　　者：丁绍越 焉玉超 张连哲 程卯生[1] 刘洋[1] DING Shaoyue;YAN Yuchao;ZHANG Lianzhe;CHENG Maosheng;LIU Yang(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Key Laboratory of Target-based Drug Design and Research Discovery of Ministry of Education,Shenyang 110016,China)

机构地区：[1]沈阳药科大学制药工程学院基于靶点的药物设计与研究教育部重点实验室,沈阳110016

出　　处：《临床药物治疗杂志》2024年第8期13-16,共4页Clinical Medication Journal

摘　　要：慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)是常见的血液肿瘤疾病。B细胞淋巴瘤-2(Bcl-2)是一种在血液肿瘤中高表达的关键细胞凋亡调节蛋白,lisaftoclax是一种Bcl-2抑制剂。在前期的临床试验中,lisaftoclax表现出良好的疗效和安全性,即使在1200 mg剂量下也未发生剂量限制性毒性。目前该药物正处于Ⅲ期临床试验的招募阶段。本文对该药物的基本信息、作用机制、药动学、有效性和安全性等方面进行概述。Chronic lymphocytic leukaemia(CLL)and small lymphocytic lymphoma(SLL)are common haematological tumour diseases.Lisaftoclax is an inhibitor of B-cell lymphoma-2(Bcl-2),a key apoptosis-regulating protein that is highly expressed in haematological malignancies.In early clinical trials,lisaftoclax demonstrated promising efficacy and safety,with no dose-limiting toxicity observed even at 1200 mg.The drug is currently in the recruitment phase of a phaseⅢclinical trial.This article provides an overview of the basic information,mechanism of action,pharmacokinetics,efficacy,and safety of the drug.

关 键 词：llisaftoclax B细胞淋巴瘤-2抑制剂 慢性淋巴细胞白血病 小淋巴细胞淋巴瘤 

分 类 号：R979.1[医药卫生—药品]